Seed Capital Solutions PLC Updates on AI Diagnostics Acquisition and Planned Move to AIM

Seed Capital Solutions pushes ahead with 4DM deal and AIM switch

Seed Capital Solutions plc (LON: SCSP) has provided a meaty progress update on its proposed acquisition of Cuarta Dimension Medica SL (4DM) and a planned move from the Main Market to AIM. If completed, the enlarged group aims to be a leading AI-driven medical diagnostics player, starting in the veterinary market with scope to expand into wider healthcare.

The documentation to complete the deal is well progressed, with some sections substantially complete. The big gating item is the audit of 4DM for the year ended 31 December 2025, which is underway and expected to complete towards the end of April. That would allow Seed Capital to finalise its AIM Admission Document shortly after.

What exactly is being proposed?

Seed Capital plans to acquire 4DM by issuing new ordinary shares in SCSP to the sellers of 4DM. No cash terms are disclosed. On completion, the combined group will focus on AI-led diagnostics, initially in veterinary applications, with ambitions to broaden into human healthcare over time.

Important note for existing holders: issuing new shares usually means dilution. The RNS does not disclose the number of shares or valuation, so the degree of dilution is not disclosed.

From Main Market to AIM: why the switch matters

SCSP’s shares have been suspended since 28 May 2025 under UK Listing Rule 13.2.1 while it pursues this Initial Transaction. The company now intends to cancel its Main Market listing and seek admission to AIM instead.

Quick refresher on the jargon:

• Admission Document: the detailed disclosure document for joining AIM.
• AIM: the London Stock Exchange’s growth market with lighter regulation and typically faster execution for growth companies.
• Cancellation: removal from the FCA’s Official List and ceasing to trade on the Main Market.

Why AIM can fit here: earlier-stage, high-growth, IP-led businesses often choose AIM for flexibility around capital raises and corporate transactions. The trade-off is lighter regulation compared with the Main Market and, sometimes, higher share price volatility. Whether that is positive or negative depends on your risk appetite.

Key milestones and expected timeline

Here is what Seed Capital has said about timing and next steps. Specific dates remain subject to change and several items are still conditional.

Milestone	Status / Timing
Listing suspension	In place since 28 May 2025
4DM audit (FY2025)	Underway, expected to complete towards end of April 2026
Admission Document	To be finalised shortly after audit completion
Notice of Cancellation	At least 20 business days’ notice required; company plans to notify during April
General meeting of shareholders	To be convened; timing not disclosed
Associated fundraise	Required as a condition; size and terms not disclosed
Completion of acquisition and AIM Admission	Targeted for the same date as Cancellation becomes effective; exact date not disclosed

What can still go wrong?

The company is clear that completion is not guaranteed. Conditions include:

• Completion of the 4DM audit.
• Completion of the associated fundraise.
• Finalisation of documentation for both the acquisition and AIM Admission.
• Shareholder approvals at a general meeting.

If the acquisition and AIM Admission do not proceed, Seed Capital intends to withdraw any notice of Cancellation. In other words, it will not delist from the Main Market if the deal falls through.

Why this update matters for SCSP shareholders

Three takeaways:

• Strategic direction: SCSP is pivoting into AI diagnostics, starting with veterinary applications. That is a hot niche with real-world demand, but it is still a specialist, early-stage arena.
• Route to market: AIM should be a better home for a growth-by-acquisition story. It can make future capital raises and corporate activity more agile, albeit with higher risk characteristics.
• Path to re-admission: Today’s update suggests the logjam is the 4DM audit. If that lands by late April and the fundraise is pulled together, investors could finally see a clear timetable to trading resumption on AIM.

Positives and watch-outs

What looks positive

• Documentation is described as well progressed, with some parts substantially complete.
• A near-term audit completion target provides a tangible catalyst.
• Clear intention to issue the 20 business days’ Cancellation notice during April, which anchors the expected timetable.
• Focus on AI-driven diagnostics gives a differentiated equity story compared with a generic cash shell.

What to be cautious about

• No certainty of completion. The fundraise and audit are both critical-path items.
• Dilution risk is real, given the deal is for new SCSP shares and an associated fundraise. The exact impact is not disclosed.
• Execution risk around moving markets and coordinating acquisition completion with AIM Admission.

My take on the risk-reward

This reads like a credible step towards wrapping up a complex reverse-style transaction. The sector focus is on-trend and the AIM switch makes strategic sense for a growth platform. The absence of deal metrics and fundraise terms means we cannot judge valuation, dilution or immediate financial runway yet.

If the audit lands on time and the Admission Document follows swiftly, April should bring a formal Cancellation notice and, with it, a more visible path to AIM. Until then, the risk sits squarely with execution. High potential if it completes, but high uncertainty until the conditions are ticked off.

What to watch next

• Completion of the 4DM FY2025 audit by end of April.
• Publication of the AIM Admission Document.
• Notice of Cancellation giving 20 business days’ warning and the proposed effective date.
• Details of the associated fundraise, including size and pricing, which are not disclosed today.
• Notice of the general meeting and the resolutions required.

Need the source?

You can find more about the company at the official site: seedcapitalsolutionsplc.com. Today’s RNS makes it clear that the information was inside information under UK MAR until publication. Beyond that, the company will update shareholders as the timetable firms up.